MedTrace Logo

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

NCT02203461 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-11-05

No results posted yet for this study

Summary

Changes in insulin resistance in healthy volunteers with normal body weight (BMI 18-25) after 14 days of STRIBILD®-, Truvada®/Kaletra® or Truvada®/Prezista®/Norvir® intake, measured by hyperinsulinemic euglycemic clamp.

Conditions

Interventions

DRUG

Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat

STRIBILD® QD, d1-14

DRUG

Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir

Truvada®/ Kaletra® 200/50 mg QD, d1-14

DRUG

Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir

Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • MUC Research GmbH

    collaborator OTHER

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Christoph D Spinner, MD · University Hospital Klinikum rechts der Isar, Technische Universitaet Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02203461 on ClinicalTrials.gov